In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.

Maria Vassilakopoulou,Jennifer Bordeaux,Veronique Neumeister,Huan Cheng,Kurt A. Schalper,Dimosthenis Skarlos,Dimitrios G Pectasides,Nicholas Pavlidis,Angelos Koutras,Helena Linardou,Evangelia Razis,Mattheos Bobos,Vassiliki Kotoula,David L. Rimm,George Fountzilas,Amanda Psyrri

In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.

2012

Maria Vassilakopoulou
Jennifer Bordeaux
Veronique Neumeister
Huan Cheng
Kurt A. Schalper
Dimosthenis Skarlos
Dimitrios G Pectasides
Nicholas Pavlidis
Angelos Koutras
Helena Linardou
Evangelia Razis
Mattheos Bobos
Vassiliki Kotoula
David L. Rimm
George Fountzilas
Amanda Psyrri

573 Background: Trastuzumab therapy is currently selected based on assessment of HER2 by either immunohistochemistry (IHC) for protein over-expression or fluorescence in situ hybridization (FISH) t...

Keywords:

Immunohistochemistry
Pathology
Fluorescence in situ hybridization
Metastatic breast cancer
In situ
Messenger RNA
Medicine
Oncology
Trastuzumab
Cohort
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations